Webinar: Combining CAR T Cells with STING Agonists to Fight Solid Tumors by InsideScientific

Combining CAR T Cells with STING Agonists to Fight Solid Tumors

About

Chimeric antigen receptor T (CAR T) cell therapy has limited efficacy in treating solid tumors, and new approaches are needed to improve patient outcomes. As a strategy to improve the therapeutic success of CAR T cells directed against solid tumors, Dr. Uslu and his colleagues at the Center for Cellular Immunotherapies, University of Pennsylvania, tested the combinatorial use of CAR T cells and IMSA101—a newly developed stimulator of interferon genes (STING) agonist. In two syngeneic tumor models, improved overall survival was observed when mice were treated with intratumorally administered IMSA101 in addition to intravenous CAR T infusion.

In this webinar, Dr. Uslu will describe how IMSA101 enhances CAR T function through STING agonist-induced IL-18 secretion and how these findings lay the foundation for advancing the combinatorial approach into a clinical setting.

Key learning objectives will include:

Learn about the importance and challenges of using CAR T cells to combat solid tumors for therapies.

Discover a novel method that enhances CAR T cell function through STING agonist-induced IL-18 secretion.

Explore features of IMSA101, a newly developed STING agonist that effectively modifies the tumor microenvironment.

Presenter

Ugur Uslu, MD

Postdoctoral Researcher, Center for Cellular Immunotherapies, University of Pennsylvania

Dr. Uslu completed his clinical training in Dermatology at Erlangen University in Germany. In addition to translational research on dendritic cell-based cancer vaccines, he worked on strategies to improve CAR T cell therapy directed against solid tumors and is currently in training as a postdoctoral research fellow in the laboratory of Dr. Carl June at the University of Pennsylvania.

Reserve Your Spot

First Name*

Last Name*

Email Address*

Organization / Company*

Job Title*

Country / Region*

At which stage of research are you currently?*

Fundamental research

Early preclinical

Late preclinical/process development

Clinical (Phase I–III)

Commercialization

I don't know

Not applicable

What part of your T cell workflow do you find the most challenging? *

Cell sourcing

Cell isolation

Cell expansion

Cell activation

Cell engineering

Other

I do not work with T cells

Please post any questions you might have for the speakers in the field below:

utm_bmcr_source